Form 4 for REGN Regeneron Pharmaceuticals
Accepted 2025-12-09 00:00:00 ET · period of report 2025-12-05 · accession 0001411984-25-000005 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-12-09 | 2025-12-05 | REGN | Van Plew Daniel P | EVP, General Mgr, Industrial | A - Grant | $0.00 | +3,715 | 26.1K | +17% | $0 |
| D | 2025-12-09 | 2025-12-08 | REGN | Van Plew Daniel P | EVP, General Mgr, Industrial | F - Tax | $712.94 | -1,906 | 24.2K | -7% | -$1.36M |
| D | 2025-12-09 | 2025-12-05 | REGN | Van Plew Daniel P | EVP, General Mgr, Industrial | A - Grant | $0.00 | +18.3K | 18.3K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-12-05 | A | A | 3,715 | $0.00 | 26,131 | D | — | — | |
| 2 | Common | Common Stock | 2025-12-08 | F | D | 1,906 | $712.94 | 24,225 | D | — | — | |
| 3 | Derivative | Non-Qualified Stock Option (right to buy) | 2025-12-05 | A | A | 18,315 | $0.00 | 18,315 | D | $726.71 · — to 2035-12-05 | 18,315 Common Stock | (F2) The stock option award vests in four equal annual installments, commencing one year after the date of grant. |